Moleculin Biotech, Inc. (MBRX) EPS Estimated At $-0.12

March 10, 2018 - By Linda Rogers

 Moleculin Biotech, Inc. (MBRX) EPS Estimated At $ 0.12

Analysts expect Moleculin Biotech, Inc. (NASDAQ:MBRX) to report $-0.12 EPS on April, 2.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.12 EPS. After having $-0.14 EPS previously, Moleculin Biotech, Inc.’s analysts see -14.29 % EPS growth. The stock increased 0.47% or $0.01 during the last trading session, reaching $2.14. About 1.05 million shares traded or 6.48% up from the average. Moleculin Biotech, Inc. (NASDAQ:MBRX) has 0.00% since March 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $55.12 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More notable recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: which released: “Mid-Afternoon Market Update: Blackline Surges After Q4 Results; Moleculin …” on February 16, 2018, also with their article: “Form SC 13G Moleculin Biotech, Inc. Filed by: SABBY MANAGEMENT, LLC” published on February 21, 2018, published: “Moleculin Biotech, Inc. (MBRX) and Pieris Pharmaceuticals, Inc. (PIRS …” on February 21, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) were released by: and their article: “Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018” published on March 06, 2018 as well as‘s news article titled: “Moleculin Biotech’s stock rockets after ‘major breakthrough’ in cancer treatment” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.